Assenagon Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Assenagon Asset Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-522,578	Closed	-$580K	–	1539
2022 Q4	$580K	Sell	522,578 -277,713	-35%	-$395K	﹤0.01%	1152
2022 Q3	$1.87M	Sell	800,291 -571,100	-42%	-$2.02M	0.01%	734
2022 Q2	$4.16M	Sell	1,371,391 -92,941	-6%	-$452K	0.02%	603
2022 Q1	$9.94M	Buy	1,464,332 +1,251,313	+587%	+$8.92M	0.03%	372
2021 Q4	$1.78M	Sell	213,019 -24	-0%	-$198	0.01%	854
2021 Q3	$1.58M	Sell	213,043 -469,827	-69%	-$2.91M	0.01%	770
2021 Q2	$4.64M	Buy	+682,870	New	+$5.67M	0.02%	498
2019 Q3	–	Sell	-207,200	Closed	-$1.03M	–	1125
2019 Q2	$1.03M	Sell	207,200 -70,900	-25%	-$376K	0.01%	711
2019 Q1	$1.72M	Buy	278,100 +230,109	+479%	+$1.11M	0.02%	564
2018 Q4	$162K	Buy	+47,991	New	+$224K	﹤0.01%	967

Other funds holding JNCE

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

ACM

Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

Assenagon Asset Management's JNCE Position: Q1 2023 in Review

Assenagon Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 522,578 shares — an estimated $580K sold.

Assenagon Asset Management first reported a position in JNCE in Q4 2018 and held it in 10 quarters. The position peaked at $9.94M in Q1 2022. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

Assenagon Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Assenagon Asset Management sold 522,578 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $580K.
Assenagon Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2018 and held it in 10 quarters.
Assenagon Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $9.94M in Q1 2022.
84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Assenagon Asset Management's 13F filing for Q1 2023, filed 18 Apr 2023.